The Sickle Cell Anemia Testing & Screening Market size was estimated at USD 437.40 million in 2025 and expected to reach USD 475.14 million in 2026, at a CAGR of 9.12% to reach USD 806.26 million by 2032.
Introduction to Sickle Cell Anemia Testing and Screening
Sickle cell anemia testing and screening sit at the intersection of newborn health, genetic diagnostics, hematology care, and population-level prevention. Sickle cell disease is one of the most common inherited blood disorders worldwide, driven by pathogenic variants in the HBB gene that affect hemoglobin structure and red blood cell function. The World Health Organization has long identified sickle cell disease as a major public health concern, particularly across sub-Saharan Africa, India, the Middle East, the Mediterranean basin, and populations with African, Middle Eastern, South Asian, Caribbean, and Latin American ancestry.